|
Originally published In Press as doi:10.1074/jbc.M106300200 on August 14, 2001
J. Biol. Chem., Vol. 276, Issue 42, 39226-39231, October 19, 2001
Characterization of the Signal Peptide Processing and
Membrane Association of Human Cytomegalovirus Glycoprotein O*
Regan N.
Theiler and
Teresa
Compton§
From the McArdle Laboratory for Cancer Research, University of
Wisconsin-Madison Medical School, Madison, Wisconsin 53706
Received for publication, July 5, 2001, and in revised form, August 9, 2001
 |
ABSTRACT |
Human cytomegalovirus (HCMV) has a structurally
complex envelope that contains multiple glycoproteins. These
glycoproteins are involved in virus entry, virus maturation, and
cell-cell spread of infection. Glycoprotein H (gH), glycoprotein L
(gL), and glycoprotein O (gO) associate covalently to form a unique
disulfide-bonded tripartite complex. Glycoprotein O was recently
discovered, and its basic structure, as well as that of the tripartite
complex, remains uncharacterized. Based on hydropathy analysis, we
hypothesized that gO could adopt a type II transmembrane orientation.
The data presented here, however, reveal that the single hydrophobic
domain of gO functions as a cleavable signal peptide that is absent
from the mature molecule. Although it lacks a membrane anchor,
glycoprotein O is associated with the membranes of HCMV-infected cells.
The sophisticated organization of the gH·gL·gO complex
reflects the intricate nature of the multicomponent entry and fusion
machinery encoded by HCMV.
 |
INTRODUCTION |
The family Herpesviridae contains eight medically
significant human pathogens. These viruses are large, enveloped
double-stranded DNA viruses that establish life-long latent infections
within their hosts. Human cytomegalovirus
(HCMV)1 causes multiple
clinical sequelae in immunocompromised hosts. HCMV is able to enter and
infect a wide variety of host cell types and can cause disease in most
organs of the body (1). This broad tropism can be attributed in part to
a complex set of viral envelope glycoproteins that play a vital role in
the viral life cycle by mediating entry of the virus into host cells,
cell-to-cell spread of infection, and maturation of virions. Most
enveloped viruses, including influenza and human immunodeficiency
virus, encode a single fusion glycoprotein that initiates attachment and fusion. In contrast, herpesviruses such as herpes simplex virus
require a minimum of four glycoproteins for fusion (2). The
multicomponent nature of herpesvirus fusion machinery provokes many
questions about the mechanisms by which large viruses with multiple
glycoproteins achieve membrane fusion.
HCMV enters host cells by a sequential cascade of molecular events
involving multiple viral and cellular proteins, culminating with fusion
of the envelope with the cellular plasma membrane (3, 4). At least two
HCMV envelope complexes are required for fusion, the homodimeric
glycoprotein B (gB), and a heteroligomeric complex thought for many
years to be composed of glycoprotein H and glycoprotein L (5-7).
Glycoprotein B, gH, and gL have homologs throughout the
Herpesviridae family (7, 8), and in all cases tested these
proteins function at the level of membrane fusion (9-13). Attempts to
reconstitute the HCMV gH complex by coexpression of the gH and gL
genes, open reading frames UL75 and UL115 of the HCMV genome,
respectively (7, 14, 15), were unsuccessful (16, 17). This failure led
to the discovery that the HCMV gH complex contained a third distinct
gene product encoded by the UL74 open reading frame, a
protein now designated gO (18). Interestingly, the UL74 gene
has homologs in the genomes of the -Herpesvirinae
subfamily, which includes HCMV, human herpesvirus 6, and human
herpesvirus 7 (18). Thus, while gH/gL heterodimers predominate in other
herpesviruses, the HCMV complex is an unusual tripartite complex
composed of gH·gL·gO. This complex appears on the surface of
HCMV-infected cells and in the envelopes of virions (18, 19).
Glycoprotein H is a type I transmembrane protein with a 719-amino acid
ectodomain and a short 6-amino acid cytoplasmic tail (15, 20), and
expression of gH without gL results in endoplasmic reticulum retention
(5, 6). gL lacks a membrane anchor and is disulfide-bonded to gH (5, 7,
15). In contrast to gH and gL, the membrane topology and organization of gO in the tripartite complex are unknown.
Analysis of the amino acid sequence of gO reveals several interesting
features, including 18 potential N-glycosylation sites and a
single hydrophobic domain that begins 14 amino acids from the N
terminus. Hydropathy analysis of this segment shows a 20-22-amino acid
region that we predicted to serve as both a signal peptide and a
membrane anchor domain (18). This region is unusual for a signal
peptide because it is inset from the amino terminus and it is long
enough to span the bilayer as a membrane anchor. If uncleaved by signal
peptidase, this region (a signal/anchor domain) would anchor gO in a
type II membrane orientation with a cytosolic amino terminus and a
carboxyl-terminal extracellular domain. In this work, we describe
experiments demonstrating that, like glycoprotein L, glycoprotein O is
a soluble protein that associates with cellular and viral membranes.
 |
EXPERIMENTAL PROCEDURES |
Cells and Viruses
Human foreskin fibroblasts and immortalized fibroblasts were
cultured as previously described (21). Human cytomegalovirus strain
AD169 was propagated and titered as previously described (21). 293-T
cells were grown in Dulbecco's modified Eagle medium supplemented with
1% penicillin-streptomycin-fungizone, 0.3% glutamine, and 10%
fetal bovine serum (Harlan Biosciences).
Plasmids
All polymerase chain reaction steps were performed using
Pfu high fidelity polymerase (Stratagene). Oligonucleotides
were synthesized at the University of Wisconsin Biotechnology Center DNA facility, where the final constructs were also verified by automated DNA sequencing. pCaggs.gO was produced by polymerase chain
reaction amplification of the full-length gO coding region using
primers 5'-GGAATTCACCATGGGGAGAAAAGAGATG-3' and
5'-AAACCGCTCGAGTTACTGCAACCACCA-3'. The product was cut with
EcoRI (5') and XhoI (3') and was inserted into
the multiple cloning site of the pCaggs vector (donated by Y. Kawaoka,
University of Wisconsin). The gO insert from pCaggs.gO was subcloned
into pCDNA3 via EcoRI/XhoI. pCaggs. gO was
generated by inserting into the pCaggs vector the region encoding amino acids 33-466 of gO. The gO insert was amplified by polymerase chain
reaction from pcDNA3.gO template using primers
5'-GGAATTCACCATGAGTAAAGCGCTTTATAATCGTCCTTG-3' and
5'-AAACCGCTCGAGTTACTGCAACCACCA-3'. The
EcoRI/XhoI-digested gO was ligated into the
pCaggs multiple cloning site. pcDNA3. gO resulted from subcloning
gO from pCaggs into pcDNA3 via EcoRI/XhoI. The pCaggs.His-gO construct encodes the complete gO coding
sequence preceded by a six-residue polyhistidine tag. It was generated in the same manner as pCaggs.gO, except that the 5' polymerase chain
reaction primer was
5'-GGAATTCACCATGCATCACCATCACCATCACATGGGGAGAAAAGAGATG-3'. pcDNA3.His-gO was generated by subcloning His-gO from pCaggs into pcDNA3 via EcoRI/XhoI.
SDS-PAGE and Immunoblotting
SDS-PAGE and immunoblotting were performed essentially as
previously described (17, 18). Briefly, nitrocellulose membranes were
washed in TBS containing 0.05% SDS, 0.5% Tween 20, and 20 mg/ml
powdered skim milk. Horseradish peroxidase-conjugated secondary antibodies were purchased from Pierce, and activity was detected using
Renaissance enhanced chemiluminescence reagent (PerkinElmer Life
Sciences). UL74 antiserum (recognizing glycoprotein
O) was previously described (18). Immunoblots probed with
UL74 antiserum were hybridized and washed in the presence of
wash buffer (described above) and additional cell lysate (100 mM dish confluent 293-T, cos-7, or IF cells lysed in 1 ml
of 1% SDS). Rabbit polyclonal antibody 6824 was previously described
(17). Monoclonal antibody 27-78 was kindly provided by W. Britt.
Murine monoclonal antibody recognizing Hsp90 was purchased from
Transduction Laboratories. Rabbit polyclonal antiserum recognizing
calreticulin was purchased from Stressgen. Rabbit polyclonal anti-His
serum (His-probe) was purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA).
Transfections
Plasmid DNA was purified by polyethylene glycol precipitation
(22). Cells were transfected by either calcium phosphate precipitation (23) or genePorter lipid transfection reagent (Gene Transfer Systems)
according to the manufacturer's instructions. Calcium phosphate
transfections were supplemented with 5 mM sodium butyrate.
Subcellular Fractionation
Preparation of Microsomes--
Immortalized human fibroblasts
were either mock-infected or infected with HCMV strain AD169 at a
multiplicity of infection of 1. Six days postinfection, the cells were
scraped into their media and collected by centrifugation. The cell
pellet was suspended in hypotonic lysis buffer (20 mM
HEPES, 1.5 mM MgCl2, 2.5 mM EDTA, 1× protease inhibitor mixture/PIC, pH 7.4) and Dounce-homogenized (final volume 15 ml). Nuclei were pelleted at 1500 × g
for 10 min and discarded. The supernatant was centrifuged for 30 min at
18,000 × g to pellet microsomal membranes. Supernatant
was precipitated with 10% trichloroacetic acid and constitutes the cytosolic fraction. Microsomal membranes were prepared from transiently transfected 293-T cells harvested 48 h post-transfection.
Alkaline Carbonate Extractions--
Microsomal membranes were
suspended in 100 µl of buffered sucrose (0.3 M sucrose
plus 10 mM Tris, pH 7.5) on ice. The suspension was
incubated on ice for 60 min in 5 ml of 0.1 M
Na2CO3, pH 11.5, and 100 mM
dithiothreitol, followed by centrifugation at 50,000 rpm in a Beckman
70.1Ti rotor (150,000 × g). The pellet was subjected to an additional round of alkaline carbonate extraction under the same
conditions. Supernatants from the washes were pooled and precipitated
with 10% trichloroacetic acid in the presence of 200 mM
iodoacetic acid. Fractions were suspended in Tris base plus nonreducing
SDS-PAGE sample buffer containing 200 mM iodoacetic acid,
heated to 65 °C, and subjected to SDS-PAGE. One-quarter cell
equivalent of the cytosolic fraction, compared with membrane fractions,
was analyzed to maintain relative equivalence of protein concentrations
among wells. For alkaline carbonate extractions of microsomes from
transfected 293-T cells, the dithiothreitol and iodoacetic acid were
omitted, and samples were subjected to reducing SDS-PAGE.
In Vitro Transcription/Translation and Immunoprecipitation
In vitro transcription and translation was performed
using the TnT T7 Quick coupled transcription/translation kit according to the manufacturer's instructions (Promega). Immunoprecipitation was
performed by diluting 45 µl of translation product in 1 ml of RIPA
(150 mM NaCl, 50 mM Tris pH 8.0, 1% Nonidet
P-40, 0.1% SDS, 0.5% deoxycholate, 1 mM EDTA) plus 0.5%
bovine serum albumin. Samples were precleared with protein A beads,
followed by incubation overnight with anti-His IgG. Complexes were
precipitated with protein A beads, washed five times with RIPA plus
bovine serum albumin, and eluted by boiling in RIPA plus reducing
SDS-PAGE sample buffer.
 |
RESULTS |
Glycoprotein O Is a Membrane-associated Protein--
To test the
hypothesis that gO is a type II membrane protein, HCMV-infected cells
were subjected to fractionation followed by alkaline carbonate
extraction. This technique solubilizes peripheral membrane proteins
while leaving transmembrane proteins associated with a membrane pellet
(24). Immunoblotting of the resulting cytosolic, carbonate-extracted,
and integral membrane proteins revealed that gO partitions in both the
peripheral and integral membrane fractions (Fig.
1). A majority of gO consistently
segregated with transmembrane proteins, while a lesser amount was
detected in the peripheral membrane fraction. Controls for each
fraction include Hsp90 (cytosol), calreticulin (soluble endoplasmic
reticulum protein), and the cytomegalovirus-encoded proteins gH and gB
(both type I integral membrane proteins), all of which were recovered in the appropriate fractions. Because gO was found in both membrane fractions in HCMV-infected cells, we hypothesized that the two types of
membrane association may result from interactions of gO with other
viral proteins.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
Subcellular fractionation of HCMV-infected
fibroblasts. Infected cells were harvested 7 days postinfection
and separated into cytosolic (C), peripheral membrane
(PM), and transmembrane (TM) fractions. The
peripheral membrane fraction consists of proteins removed from
membranes by alkaline carbonate treatment, including the ER chaperone
protein calreticulin. Transmembrane proteins include those remaining in
the membrane after alkaline carbonate treatment as demonstrated by the
type I integral membrane proteins gH and gB. Protein fractions were
subjected to SDS-PAGE followed by immunoblotting with antibodies to
glycoprotein O, Hsp90, calreticulin, glycoprotein H, and glycoprotein B
as indicated.
|
|
To examine gO in a system isolated from other viral gene products, a
similar experiment was conducted using transiently transfected 293-T
cells expressing gO (Fig. 2). Although it
partitioned differentially in HCMV-infected cells, gO was solely
detected in the soluble membrane content fraction of transfected cells.
This result, shown in Figs. 1 and 2, demonstrated that gO is more
strongly associated with membranes of infected cells than those of
transfected cells, suggesting that the affinity of membrane association
of gO differs with the context of expression.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 2.
Subcellular fractionation of transfected
293-T cells. 293-T cells were harvested 48 h after
transfection with plasmids expressing HCMV gO (top
three panels) or gH (bottom
panel). Cells were fractionated as in Fig. 1, followed by
SDS-PAGE and immunoblotting with antibodies as indicated to the
right of each panel.
|
|
The Signal Peptide of gO Is Cleaved from the Mature
Molecule--
Initial experiments suggested that gO was not a
transmembrane protein. We further tested this hypothesis using two
recombinant forms of gO (Fig. 3). One
form, designated gO, lacked the amino-terminal 32 amino acids
comprising the putative signal/anchor domain. A second construct,
designated His-gO, encoded a six-residue polyhistidine sequence on the
extreme amino terminus of the protein. The full-length peptide backbone
of gO was predicted to be 466 amino acids long, with a molecular
mass of ~51 kDa (18, 20). Loss of the 32-amino acid N-terminal
hydrophobic sequence predicted a protein of ~48 kDa for gO. For
comparison of the backbone sizes of gO and gO, N-linked
glycans were removed by endoglycosidase H treatment of gO-transfected
cell lysates and gO-transfected cell lysates. If the signal peptide
of gO were uncleaved, we would expect to see a difference in
electrophoretic mobility corresponding to the 3-kDa size difference
between the peptide backbones of gO and gO (Fig. 3). As shown in
Fig. 4, the deglycosylated peptide backbones of gO and gO migrated similarly when subjected to
SDS-PAGE, demonstrating that these proteins were the same 48-kDa size
(Fig. 4A) and that the signal peptide of gO was cleaved from
the mature protein. The identity of the lower 40-kDa band produced by
transfection of gO is unknown but may represent a degradation
product. Note also that removal of the signal peptide in gO
abolished glycosylation, as evidenced by its electrophoretic mobility
and insensitivity to glycosidase digestion. To confirm that
experiments performed on gO produced by transfection reflected the
forms of gO found in HCMV-infected cells, the peptide backbone size of
gO was determined in both infected and transfected cells. Cell lysates
were treated with peptide N-glycosidase F to remove all
N-linked glycans and were then subjected to SDS-PAGE
followed by immunoblotting. The results in Fig. 4B show that
the backbone peptide of gO had the same electrophoretic mobility in
transfected and infected cells and that signal peptide processing was
similar in these two systems.

View larger version (9K):
[in this window]
[in a new window]
|
Fig. 3.
Amino acid sequence of the putative
signal/anchor domain. The amino terminus of gO contains a
hydrophobic region (underlined), which may serve as both a
signal peptide and a membrane anchor domain. Removal of the majority of
this domain in the mutant designated gO allows for translation
initiation at methionine 33. The addition of an amino-terminal
polyhistidine tag in His-gO plasmids allows specific detection of this
region after translation.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 4.
The peptide backbone size of gO is consistent
with signal peptide cleavage. A, 293-T cells were
transfected with plasmids expressing gO (lanes 3 and 4) or gO (lanes 5 and
6). Cells were harvested 48 h post-transfection, lysed
in RIPA buffer, and subjected to endoglycosidase H (or mock) treatment.
Analysis by SDS-PAGE and immunoblotting demonstrates that the
glycan-free backbone of processed gO has equivalent mobility to that
expressed by gO. Note that gO does not undergo glycosylation.
B, HCMV-infected and mock-infected fibroblasts were
harvested on day seven of infection, lysed in RIPA buffer, and
subjected to peptide N-glycosidase F digestion. The
lane marked Transfected indicates that
gO-transfected 293-T cells were lysed and treated with peptide
N-glycosidase.
|
|
To further test that the N-terminal signal sequence
undergoes signal peptidase cleavage, a polyhistidine tag was added to the extreme amino terminus of gO (Fig. 3). Detection of His-gO expression by immunoblotting with anti-gO serum verified that the
recombinant construct expressed glycosylated gO, indicating that the
tag did not alter signal peptide function (Fig.
5A). Immunoblotting with
anti-His serum, however, showed that the tag was absent from processed
gO (Fig. 5B). Using in vitro translation, we
confirmed that the amino-terminal His tag was translated as part of gO
and that it was recognized by our antibody (Fig.
6). Thus, our inability to detect the His
tag in cells resulted from cleavage of the amino terminus rather than
from internal translation initiation. Additionally, in vitro
translation of gO and gO clearly showed a difference in mobility,
indicating that their identical electrophoretic mobility upon
expression in cells (Fig. 4) resulted from cleavage of the signal
peptide during ER translocation.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 5.
The amino-terminal polyhistidine tag is
absent from mature gO. Transfected 293-T cells were lysed 48 h post-transfection and subjected to SDS-PAGE and immunoblotting.
Left, lysates blotted with anti-gO serum show expression of
gO after transfection with pCaggs.gO (gO) or pCaggs.His-gO
(His-gO). Right, cell lysates probed with
anti-His serum demonstrate the presence of a polyhistidine tag on the
control protein encoded by pHM6 ( -gal His), but not on
His-gO.
|
|

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 6.
The amino-terminal polyhistidine tag is
translated. Coupled transcription and translation of the indicated
plasmids was driven by the T7 promoter of pcDNA3 or pHM6 in the
presence of radiolabeled methionine. Samples were analyzed by SDS-PAGE
and autoradiography before (left) or after
(right) immunoprecipitation with anti-His serum.
|
|
 |
DISCUSSION |
The gH·gL·gO complex undergoes multiple steps of assembly
during its transit through the secretory pathway of HCMV-infected cells
(19). With a mass greater than 240 kDa, the mature complex is a
disulfide-linked heteroligomer of unknown stoichiometry (6, 7, 25, 26).
Early studies of HCMV gH and gL showed that gH needs gL for proper
trafficking through the secretory apparatus (5, 6). When gH is
expressed in the presence of gL, complexes of the two proteins reach
the cell surface but are not secreted into the medium. Removal of the
C-terminal membrane anchor of gH results in secretion of soluble
gH·gL complexes, and when gL is expressed alone it can also be found
in the medium (5, 6). These data led to the conclusion that gH contains
a C-terminal membrane anchor and that gL is held in the viral envelope
by its disulfide linkage(s) to gH. Beyond this basic characterization, little is known about the structure of the gH·gL·gO complex.
Based on sequence analysis, we hypothesized that the 20-amino acid
hydrophobic domain on the amino terminus of gO serves as a signal
peptide and membrane anchor. In general, a signal peptide longer than
15-18 amino acids indicates that signal peptidase is unlikely to
cleave the nascent chain, leaving an intact amino-terminal transmembrane domain (27). Several viral envelope proteins, including
influenza neuraminidase, are known to have this membrane orientation
(28-30). As a novel member of the disulfide-linked gH·gL complex, gO
is unusual in that it is a viral envelope protein that does not need a
transmembrane domain for membrane association. Covalent and/or
noncovalent association with gH may suffice to tether gO to the viral
envelope. Although we hypothesized, based on the amino acid sequence,
that gO contained a membrane anchor, we addressed the question experimentally.
One established method for separating integral membrane proteins from
soluble, membrane-associated proteins involves washing vesicular
membranes in alkaline carbonate. Alkaline treatment converts membrane
vesicles into sheets, releasing ER and Golgi contents into the
supernatant and leaving transmembrane proteins in the membrane pellet
(24). From previous work, it is known that processing of gO in the ER
occurs prior to its association with gH·gL complexes and that gO can
be found as a monomer for several hours after synthesis (19). We
propose that the subset of glycosylated gO that is not stably bound to
gH·gL complexes may be the same portion that can be extracted from
membranes by alkaline carbonate treatment. Results in Fig. 2 show that
gO, when expressed alone, can be completely extracted from membranes. Our results suggest that alkaline carbonate extraction solubilizes proteins from membrane vesicles in a context-specific fashion. The
implication of such selective extraction is that proteins, such as gO,
that stably associate with integral membrane proteins via noncovalent
or covalent interactions cannot be reliably analyzed by alkaline
extraction alone.
Faced with the experimental challenge of demonstrating the absence,
rather than the presence, of a membrane-spanning domain, we created an
epitope-tagged recombinant form of gO. The cumulative evidence from the
His-tagged protein experiment and previous studies demonstrated that
the signal peptide of gO is cleaved and that gO is a soluble protein.
Thus, our working model of the gH·gL·gO complex asserts that
glycoproteins H, L, and O are held in the viral envelope by the single
transmembrane domain of gH (Fig. 7). We
also know that assembly of the complex occurs sequentially in the ER
and that gO acquires terminal modifications while traversing the Golgi
en route to the cell surface (19). It is not known, however, where
final envelopment of the virus occurs.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 7.
Model of HCMV cell entry. HCMV adheres
to the surface of human fibroblasts by low affinity interactions
between gB and cellular heparan sulfate proteoglycans (3). This
adhesion quickly transitions to a state of stable binding, or docking,
as gB attaches to its nonheparin cellular receptor (47). Docking
also results in activation of an intracellular signal transduction
cascade, with characteristics similar to that induced by interferon
binding (48, 49). At least one additional step, priming, is necessary
for membrane fusion to occur. Binding of the gH·gL·gO complex to
unidentified cellular component(s) precedes the final fusion of the
viral envelope with cellular membranes (40). Although specific events,
such as Ca2+ flux or endosomal acidification, are known to
trigger the transition to membrane fusion in other systems, no such
trigger has been identified for herpesvirus-mediated membrane
fusion.
|
|
The tripartite gH·gL·gO complex is unusual among viral fusion
glycoproteins and has to date been studied only in HCMV. The gH and gL
components of the complex have characterized homologs among all
herpesviruses examined (31-37), but gO homologs are found only in the
herpesviruses (18). Glycoproteins H and L are essential components
of the virus (38) and are necessary for fusion of the viral envelope
with the host cell membrane (9, 39, 40). In contrast, recent work has
shown that gO is not essential for viral replication in tissue culture
but that a gO knockout virus has a severely attenuated phenotype (38).
Preliminary data from our laboratory also support involvement of gO in
the fusion process, and studies are ongoing to elucidate the exact role
that gO plays in viral entry and cell to cell spread of infection.
The Herpesviridae are unique among viruses in the complexity
of their glycoprotein coats. Thus, models of membrane fusion derived
from single glycoprotein viral systems are of only moderate utility in
our efforts to dissect the mechanisms of viral entry and cell to cell
spread of HCMV. Perhaps more relevant are models of intracellular
vesicle transport and membrane fusion, such as neurotransmitter release
from synaptic vesicles. The multiprotein interactions between v-SNAREs
and t-SNAREs as well as the sequential nature of membrane docking and
fusion steps closely resemble the stages of HCMV fusion with host cell
membranes (41). Additionally, the core fusion complex of
SNAP-25/syntaxin is composed of an integral membrane protein, syntaxin,
which targets SNAP-25 to membranes (42). Several other proteins have
been identified that bind to and positively or negatively regulate
SNAREs in the neuron, including those proteins mediating
calcium-triggered activation of fusion (41, 43, 44). Multiple
additional proteins of uncharacterized function have also been
identified in the envelope of HCMV (see Refs. 20 and 45; reviewed in
Ref. 46) and may contribute to or regulate the fusion machinery in
response to unknown triggering events. Examination of the mechanisms of
intracellular membrane fusion may ultimately facilitate our
understanding of the complex nature of HCMV-induced membrane fusion.
 |
FOOTNOTES |
*
This research was funded by United States Public Health
Service Grant RO1 A144203.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Supported by Molecular Biosciences Training Grant T32 GM 07215.
§
To whom correspondence should be addressed: McArdle Laboratory for
Cancer Research, 1400 University Ave., Madison, WI 53706. Tel.:
608-262-1474; Fax: 608-262-2824; E-mail:
tcompton@facstaff.wisc.edu.
Published, JBC Papers in Press, August 14, 2001, DOI 10.1074/jbc.M106300200
 |
ABBREVIATIONS |
The abbreviations used are:
HCMV, human
cytomegalovirus;
gB, gH, gL, and gO, glycoprotein B, H, L, and O,
respectively;
PAGE, polyacrylamide gel electrophoresis;
RIPA, radioimmune precipitation;
ER, endoplasmic reticulum.
 |
REFERENCES |
| 1.
|
Sinzger, C.,
and Jahn, G.
(1996)
Intervirology
39,
302-319[Medline]
[Order article via Infotrieve]
|
| 2.
|
Turner, A.,
Bruun, B.,
Minson, T.,
and Browne, H.
(1998)
J. Virol.
72,
873-875[Abstract/Free Full Text]
|
| 3.
|
Compton, T.,
Nowlin, D. M.,
and Cooper, N. R.
(1993)
Virology
193,
834-841[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Nowlin, D. M.,
Cooper, N. R.,
and Compton, T.
(1991)
J. Virol.
65,
3114-3121[Abstract/Free Full Text]
|
| 5.
|
Spaete, R. R.,
Perot, K.,
Scott, P. I.,
Nelson, J. A.,
Stinski, M. F.,
and Pachl, C.
(1993)
Virology
193,
853-861[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Kaye, J. F., U. A., G.,
and Minson, A. C.
(1992)
J. Gen. Virol.
73,
2693-2698[Abstract/Free Full Text]
|
| 7.
|
Cranage, M. P.,
Smith, G. L.,
Bell, S. E.,
Hart, H.,
Brown, C.,
Bankier, A. T.,
Tomlinson, P.,
Barrell, B. G.,
and Minson, T. C.
(1988)
J. Virol.
62,
1416-1422[Abstract/Free Full Text]
|
| 8.
|
Cranage, M. P.,
Kouzarides, T.,
Bankier, A. T.,
Satchwell, S.,
Weston, K.,
Tomlinson, P.,
Barrell, B.,
Hart, H.,
Bell, S. E.,
Minson, A. C.,
and Smith, G. L.
(1986)
EMBO J.
5,
3057-3063[Medline]
[Order article via Infotrieve]
|
| 9.
|
Milne, R. S.,
Paterson, D. A.,
and Booth, J. C.
(1998)
J. Gen. Virol.
79,
855-865[Abstract]
|
| 10.
|
Baghian, B.,
ZHuang, L.,
Newman, S.,
Jayachandra, S.,
and Kousoulas, K. G.
(1993)
J. Virol.
67,
2396-2401[Abstract/Free Full Text]
|
| 11.
|
Bold, S.,
Ohlin, M.,
Garten, W.,
and Radsak, K.
(1996)
J. Gen. Virol.
77,
2297-2302[Abstract/Free Full Text]
|
| 12.
|
Cai, W.,
Gu, B.,
and Person, S.
(1988)
J. Virol.
62,
2596-2604[Abstract/Free Full Text]
|
| 13.
|
Navarro, D.,
Paz, P.,
and Pereira, L.
(1992)
Virology
186,
99-112[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Leatham, M. P.,
Witte, P. R.,
and Stinski, M. F.
(1991)
J. Virol.
65,
6144-6153[Abstract/Free Full Text]
|
| 15.
|
Pachl, C.,
Probert, W. S.,
Hermsen, K. M.,
Masiarz, F. R.,
Rasmussen, L.,
Merrigan, T. C.,
and Spaete, R. R.
(1989)
Virology
169,
418-426[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Li, L.,
Nelson, J. A.,
and Britt, W. J.
(1997)
J. Virol.
71,
3090-3097[Abstract]
|
| 17.
|
Huber, M. T.,
and Compton, T.
(1997)
J. Virol.
71,
5391-5398[Abstract]
|
| 18.
|
Huber, M. T.,
and Compton, T.
(1998)
J. Virol.
72,
8191-8197[Abstract/Free Full Text]
|
| 19.
|
Huber, M. T.,
and Compton, T.
(1999)
J. Virol.
73,
3886-3892[Abstract/Free Full Text]
|
| 20.
|
Chee, M. S.,
Bankier, A. T.,
Beck, S.,
Bohni, R.,
Brown, C. M.,
Cerny, R.,
Horsnell, T.,
Hutchison III, C. A.,
Kouzarides, T.,
Martignetti, J. A.,
Preddie, E.,
Satchwell, S. C.,
Tomlinson, P.,
Weston, K. M.,
and Barrell, B. G.
(1990)
Curr. Topics Microbiol. Immunol.
154,
125-169[Medline]
[Order article via Infotrieve]
|
| 21.
|
Compton, T.
(1993)
J. Virol.
67,
3644-3648[Abstract/Free Full Text]
|
| 22.
|
Sambrook, J.,
Fritsch, E.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, pp. 1.38-1.41, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 23.
|
Graham, F. L.,
and van der Eb, A. J.
(1973)
Virology
52,
456-67[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Fujiki, Y.,
Hubbard, A. L.,
Fowler, S.,
and Lazarow, P. B.
(1982)
J. Cell Biol.
93,
97-102[Abstract/Free Full Text]
|
| 25.
|
Gretch, D. R.,
Kari, B.,
Rasmussen, L.,
Gehrz, R. C.,
and Stinski, M. F.
(1988)
J. Virol.
62,
875-881[Abstract/Free Full Text]
|
| 26.
|
Britt, W. J.
(1984)
Virology
135,
369-378[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Nilsson, I.,
Whitley, P.,
and von Heijne, G.
(1994)
J. Cell Biol.
126,
1127-1132[Abstract/Free Full Text]
|
| 28.
|
Bos, T. J.,
Davis, A. R.,
and Nayak, D. P.
(1984)
Proc. Natl. Acad. Sci. U. S. A.
81,
2327-2331[Abstract/Free Full Text]
|
| 29.
|
Wilson-Rawls, J.,
and Wold, W. S.
(1993)
Virology
195,
6-15[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Roberts, S. R.,
Lichtenstein, D.,
Ball, L. A.,
and Wertz, G. W.
(1994)
J. Virol.
68,
4538-4546[Abstract/Free Full Text]
|
| 31.
|
Grose, C.
(1991)
Rev. Infect. Dis.
3,
S960-S963
|
| 32.
|
Yaswen, L. R.,
Stephens, E. B.,
Davenport, L. C.,
and Hutt-Fletcher, L. M.
(1993)
Virology
195,
387-396[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Heineman, T.,
Gong, M.,
Sample, J.,
and Kieff, E.
(1988)
J. Virol.
62,
1101-1107[Abstract/Free Full Text]
|
| 34.
|
Rawlinson, W. D.,
Farrell, H. E.,
and Barrell, B. G.
(1996)
J. Virol.
70,
8833-8849[Abstract]
|
| 35.
|
Lindquester, G. J.,
O'Brian, J. J.,
Anton, E. D.,
Greenamoyer, C. A.,
Pellett, P. E.,
and Dambaugh, T. R.
(1997)
Arch. Virol.
142,
103-123[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Josephs, S. F.,
Ablashi, D. V.,
Salahuddin, S. Z.,
Jagodzinski, L. L.,
Wong, S. F.,
and Gallo, R. C.
(1991)
J. Virol.
65,
5597-5604[Abstract/Free Full Text]
|
| 37.
|
Mukai, T.,
Hata, A.,
Isegawa, Y.,
and Yamanishi, K.
(1997)
Microbiol. Immunol.
41,
43-50[Medline]
[Order article via Infotrieve]
|
| 38.
|
Messerle, M.,
Hahn, G.,
Brune, W.,
and Koszinowski, U. H.
(2000)
Adv. Virus Res.
55,
463-478[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Baldwin, B. R.,
Kleinberg, M.,
and Keay, S.
(1996)
Biochem. Biophys. Res. Commun.
219,
668-673[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Keay, S.,
and Baldwin, B.
(1991)
J. Virol.
65,
5124-5128[Abstract/Free Full Text]
|
| 41.
|
Mochida, S.
(2000)
Neurosci. Res.
36,
175-182[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Vogel, K.,
Cabaniols, J. P.,
and Roche, P. A.
(2000)
J. Biol. Chem.
275,
2959-2965[Abstract/Free Full Text]
|
| 43.
|
Ilardi, J. M.,
Mochida, S.,
and Sheng, Z. H.
(1999)
Nat. Neurosci.
2,
119-124[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Lao, G.,
Scheuss, V.,
Gerwin, C. M.,
Su, Q.,
Mochida, S.,
Rettig, J.,
and Sheng, Z. H.
(2000)
Neuron
25,
191-201[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Baldick, C. J., Jr.,
and Shenk, T.
(1996)
J. Virol.
70,
6097-6105[Abstract]
|
| 46.
|
Spaete, R. R.,
Gehrz, R. C.,
and Landini, M. P.
(1994)
J. Gen. Virol.
75,
3287-3308[Abstract/Free Full Text]
|
| 47.
|
Boyle, K. A.,
and Compton, T.
(1998)
J. Virol.
72,
1826-1833[Abstract/Free Full Text]
|
| 48.
|
Boyle, K. A.,
Pietropaolo, R. L.,
and Compton, T.
(1999)
Mol. Cell. Biol.
19,
3607-3613[Abstract/Free Full Text]
|
| 49.
|
Simmen, K. A.,
Singh, J.,
Luukkonen, B. G.,
Lopper, M.,
Bittner, A.,
Miller, N. E.,
Jackson, M. R.,
Compton, T.,
and Fruh, K.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
7140-7145[Abstract/Free Full Text]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
X. J. Jiang, B. Adler, K. L. Sampaio, M. Digel, G. Jahn, N. Ettischer, Y.-D. Stierhof, L. Scrivano, U. Koszinowski, M. Mach, et al.
UL74 of Human Cytomegalovirus Contributes to Virus Release by Promoting Secondary Envelopment of Virions
J. Virol.,
March 15, 2008;
82(6):
2802 - 2812.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. W. Boehme, M. Guerrero, and T. Compton
Human Cytomegalovirus Envelope Glycoproteins B and H Are Necessary for TLR2 Activation in Permissive Cells
J. Immunol.,
November 15, 2006;
177(10):
7094 - 7102.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Guma, M. Budt, A. Saez, T. Brckalo, H. Hengel, A. Angulo, and M. Lopez-Botet
Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts
Blood,
May 1, 2006;
107(9):
3624 - 3631.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Sadaoka, K. Yamanishi, and Y. Mori
Human herpesvirus 7 U47 gene products are glycoproteins expressed in virions and associate with glycoprotein H.
J. Gen. Virol.,
March 1, 2006;
87(Pt 3):
501 - 508.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. R. Kinzler and T. Compton
Characterization of Human Cytomegalovirus Glycoprotein-Induced Cell-Cell Fusion
J. Virol.,
June 15, 2005;
79(12):
7827 - 7837.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Hansen, L. I. Strelow, D. C. Franchi, D. G. Anders, and S. W. Wong
Complete Sequence and Genomic Analysis of Rhesus Cytomegalovirus
J. Virol.,
June 15, 2003;
77(12):
6620 - 6636.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Rasmussen, A. Geissler, C. Cowan, A. Chase, and M. Winters
The Genes Encoding the gCIII Complex of Human Cytomegalovirus Exist in Highly Diverse Combinations in Clinical Isolates
J. Virol.,
October 2, 2002;
76(21):
10841 - 10848.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|